Company intelligence / Profile preview

AccuBioTech

Beijing, China

Ownership: Private
Development stage: Other

Overview

AccuBioTech's rapid in vitro diagnostic (IVD) tests and analyzers are CE-marked for over 80 products; they cover infectious disease detection (HIV, Dengue, Influenza, Malaria, Monkeypox), fertility tests, drug abuse, tumor markers, inflammation markers, and provide reliable, cost-effective diagnostics in hospital, lab, and home settings over 50 countries[1][2][5][6].

Therapeutic areas: NephrologyCardiovascularWomen's HealthInfectious DiseasesPsychiatryOncology
Modalities: Immunochromatographic AssayELISAMonoclonal antibodyPolyclonal antibody
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on AccuBioTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AccuBioTech.

Explore the full profile